2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 93

An HLA-C Amino Acid Variant in Addition to HLA-B*27 Confers Risk for Ankylosing Spondylitis in the Korean Population
Abstract Number: 94

NGS Panel for the Detection of Monogenic SLE in Children: Initial Results
Abstract Number: 95

Validation of Differential Methylation in Paternally Versus Maternally Transmitted Psoriatic Disease
Abstract Number: 96

The ABCG2 polymorphism Is Associated with Hyperuricemia in a Community-Based Korean Cohort
Abstract Number: 97

Genomic Sequencing of Uric Acid Metabolizing and Clearing Genes in Relationship to Xanthine Oxidase Inhibitor Dose
Abstract Number: 98

The Mitochondrial DNA (mtDNA) Haplogroups Influence the Risk of Incidence Knee OA. Replication Study Including Data from Check and OAI Cohorts
Abstract Number: 99

Personalised Genetic Medicine: HLA-DRB1 Amino Acid Positions 11, 71 and 74 Predict Inflammation Level, Disease Activity and Disability in Rheumatoid Arthritis
Abstract Number: 100

Validation of a Distinct Psoriatic Arthritis Risk Variant at IL23R
Abstract Number: 101

New Technologies for Typing Self-Identifying Antigens Encoded By HLA Genes Provide Cost-Effective Alternatives to Identifying B27 Allele Status in Rheumatoid Arthritis Subjects
Abstract Number: 102

Xanthine Oxidase Gene Variants and Their Association with Blood Pressure and Incident Hypertension: A Population Based Study
Abstract Number: 103

Axial Disease in Psoriatic Arthritis: Genetic Biomarkers of Psoriatic Spondyloarthritis
Abstract Number: 104

A Genome-Wide Association Study Identifies SLC8A3 As a Susceptibility Locus for ACPA-Positive Rheumatoid Arthritis
Abstract Number: 105

Analysis of the Association of PTGER4 Gene Variants with Radiological Joint Damage in Rheumatoid Arthritis
Abstract Number: 106

Does the Timing of Phenotype Assessment Influence Association Results in Pharmacogenetics Studies of Anti-TNF Response in Rheumatoid Arthritis?
Abstract Number: 107

FCGR3A-158V/F Polymorphism Is Associated with a Lower Response Rate to Tumor Necrosis FactorÂ Î± Blockers in Early Axial Spondyloarthritis: Data from the DESIR Cohort

« Previous Page
1
…
6
7
8
9
10
…
218
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].